Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Atul Pande Biography and Net Worth

Director of Immunovant

Dr. Atul Pande M.D. serves as Independent Director of the Company. Since the closing of the Business Combination in December 2019, Dr. Pande has served as a member of Immunovant’s board of directors. Dr. Pande has extensive experience in treatment development across multiple disease areas. He is currently an independent board member of Axovant Gene Therapies, Karuna Therapeutics, Autifony Therapeutics, and Perception Neurosciences. He previously served as the Chief Medical Officer of PureTech Health, Chief Medical Officer of Tal Medical, and medical advisor to PureTech Health. Since April 2014, he has also served as President of Verity BioConsulting, a drug development consulting firm that provides services to clients in the biopharmaceutical business. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. He has been on the Scientific Advisory Boards of Cennerv Pharma and Centrexion Corporation. Our board of directors believes that Dr. Pande’s medical background and his significant knowledge of the biopharmaceutical industry qualifies him to serve as a member of our board of directors.

What is Atul Pande's net worth?: The estimated net worth of Atul Pande is at least $65,200.00 as of September 1st, 2021. Dr. Pande owns 2,500 shares of Immunovant stock worth more than $65,200 as of December 25th. This net worth evaluation does not reflect any other assets that Dr. Pande may own. Learn More about Atul Pande's net worth.
How do I contact Atul Pande?: The corporate mailing address for Dr. Pande and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Atul Pande's contact information.
Has Atul Pande been buying or selling shares of Immunovant?: Atul Pande has not been actively trading shares of Immunovant within the last three months. Most recently, on Friday, August 13th, Atul Pande bought 5,000 shares of Immunovant stock. The stock was acquired at an average cost of $7.98 per share, with a total value of $39,900.00. Learn More on Atul Pande's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, insiders at the sold shares 38 times. They sold a total of 226,233 shares worth more than $6,598,313.84. The most recent insider tranaction occured on November, 20th when insider Mark S Levine sold 3,650 shares worth more than $92,892.50. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 11/20/2024.

Atul Pande Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/13/2021	Buy	5,000	$7.98	$39,900.00

Atul Pande Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $26.08

$25.44

$26.24

50 Day Range

MA: $28.40

$25.22

$31.42

2 Week Range

Now: $26.08

$24.61

$45.58

Volume

908,488 shs

Average Volume

1,068,167 shs

Market Capitalization

$3.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.